Nexeon MedSystems Competitors

Non-Invasive Monitoring Systems (OTCMKTS:NIMU) and Nexeon MedSystems (OTCMKTS:NXNN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Valuation and Earnings

This table compares Non-Invasive Monitoring Systems and Nexeon MedSystems' revenue, earnings per share and valuation.

Profitability

This table compares Non-Invasive Monitoring Systems and Nexeon MedSystems' net margins, return on equity and return on assets.

Risk & Volatility

Non-Invasive Monitoring Systems has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Nexeon MedSystems has a beta of 12.71, indicating that its stock price is 1,171% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Non-Invasive Monitoring Systems and Nexeon MedSystems, as provided by MarketBeat.

Summary

Nexeon MedSystems beats Non-Invasive Monitoring Systems on 3 of the 3 factors compared between the two stocks.

ReShape Lifesciences (OTCMKTS:RSLSD) and Nexeon MedSystems (OTCMKTS:NXNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Nexeon MedSystems has a beta of 12.71, indicating that its stock price is 1,171% more volatile than the S&P 500.

Earnings & Valuation

This table compares ReShape Lifesciences and Nexeon MedSystems' revenue, earnings per share (EPS) and valuation.

Nexeon MedSystems has lower revenue, but higher earnings than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Nexeon MedSystems' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings for ReShape Lifesciences and Nexeon MedSystems, as provided by MarketBeat.

Summary

Nexeon MedSystems beats ReShape Lifesciences on 4 of the 5 factors compared between the two stocks.

Magna-Lab (OTCMKTS:MAGAA) and Nexeon MedSystems (OTCMKTS:NXNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Profitability

This table compares Magna-Lab and Nexeon MedSystems' net margins, return on equity and return on assets.

Risk and Volatility

Magna-Lab has a beta of 5.2, indicating that its stock price is 420% more volatile than the S&P 500. Comparatively, Nexeon MedSystems has a beta of 12.71, indicating that its stock price is 1,171% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Magna-Lab and Nexeon MedSystems, as provided by MarketBeat.

Earnings & Valuation

This table compares Magna-Lab and Nexeon MedSystems' revenue, earnings per share (EPS) and valuation.

Summary

Nexeon MedSystems beats Magna-Lab on 2 of the 3 factors compared between the two stocks.

Nexeon MedSystems (OTCMKTS:NXNN) and Aradigm (OTCMKTS:ARDMQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Nexeon MedSystems and Aradigm's net margins, return on equity and return on assets.

Risk and Volatility

Nexeon MedSystems has a beta of 12.71, indicating that its stock price is 1,171% more volatile than the S&P 500. Comparatively, Aradigm has a beta of 2.91, indicating that its stock price is 191% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Nexeon MedSystems and Aradigm, as reported by MarketBeat.

Valuation and Earnings

This table compares Nexeon MedSystems and Aradigm's revenue, earnings per share and valuation.

Summary

Nexeon MedSystems beats Aradigm on 1 of the 1 factors compared between the two stocks.

Nexeon MedSystems (OTCMKTS:NXNN) and IMRIS (OTCMKTS:IMRSQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Nexeon MedSystems and IMRIS's net margins, return on equity and return on assets.

Risk and Volatility

Nexeon MedSystems has a beta of 12.71, indicating that its stock price is 1,171% more volatile than the S&P 500. Comparatively, IMRIS has a beta of -10.69, indicating that its stock price is 1,169% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Nexeon MedSystems and IMRIS, as reported by MarketBeat.

Valuation and Earnings

This table compares Nexeon MedSystems and IMRIS's revenue, earnings per share and valuation.

Summary

Nexeon MedSystems beats IMRIS on 1 of the 1 factors compared between the two stocks.

Nexeon MedSystems (OTCMKTS:NXNN) and SpectraScience (OTCMKTS:SCIE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Nexeon MedSystems and SpectraScience's net margins, return on equity and return on assets.

Risk and Volatility

Nexeon MedSystems has a beta of 12.71, indicating that its stock price is 1,171% more volatile than the S&P 500. Comparatively, SpectraScience has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Nexeon MedSystems and SpectraScience, as reported by MarketBeat.

Valuation and Earnings

This table compares Nexeon MedSystems and SpectraScience's revenue, earnings per share and valuation.

Summary

Nexeon MedSystems beats SpectraScience on 1 of the 1 factors compared between the two stocks.